Middle East & Africa Biologics Market Size & Outlook

Name: Middle East & Africa Biologics Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The biologics market in Middle East & Africa is expected to reach a projected revenue of US$ 44,003.8 million by 2033. A compound annual growth rate of 9.2% is expected of Middle East & Africa biologics market from 2026 to 2033.

Middle East & Africa biologics source outlook (Revenue, USD million, 2021-2033)
- Microbial
- Mammalian
- Others
Middle East & Africa biologics product outlook (Revenue, USD million, 2021-2033)
- Monoclonal antibodies (MABs)
  - Therapeutic
    - Direct MAB Agents
    - Targeting MAB Agents
  - Diagnostics
    - Biochemical Analysis
    - Diagnostic Imaging
  - Protein Purification
  - Others
- Vaccines
- Recombinant Proteins
- Antisense & RNAi Therapeutics
- Others
Middle East & Africa biologics disease category outlook (Revenue, USD million, 2021-2033)
- Oncology
  - Monoclonal antibodies (MABs)
  - Vaccines
  - Recombinant Proteins
  - Antisense & RNAi Therapeutics
  - Others
- Infectious Diseases
  - Vaccines
  - MABs
  - Antisense & RNAi Therapeutics
  - Recombinant Proteins
  - Others
- Immunological Disorders
- Cardiovascular Disorders
- Haematological Disorders
- Others
Middle East & Africa biologics manufacturing outlook (Revenue, USD million, 2021-2033)
- In-house
- Outsourced

Middle East & Africa Biologics Market Size & Outlook

Sign up - it's easy, and free!